GSDMD and neoplasm: Although the levels of IL-18 and IL-1β were expectedly reduced in the TME by Gsdmd knockout or DSF treatment (Supplemental Figure 2Y), neutralizing IL-18 and IL-1β did not change the difference in tumor growth between Gsdmd–/– or DSF-treated mice and WT untreated mice (Supplemental Figure 2Z), nor the difference in lymphocyte infiltration and function (Supplemental Figure 2, AA and AB).